Topiramate extended-release - Spherics

Drug Profile

Topiramate extended-release - Spherics

Alternative Names: SRx-502; Topiramate XR - Spherics

Latest Information Update: 23 Nov 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spherics
  • Class Antiepileptic drugs; Antimigraines; Hexoses; Ketoses; Neuroprotectants; Obesity therapies; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Epilepsy; Migraine

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 15 Sep 2008 Additional adverse events data from a clinical trial in patients with Epilepsy released by Spherics
  • 26 Aug 2008 Phase-II clinical trials in Epilepsy in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top